|Description||This active molecular also known as AC220 and AC010220, is developed as a new second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM, ten fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Now Quizartinib is in Phase-III clinical trials in Acute myeloid leukaemia.|
|B0084-157290||100 mg||$199||In stock|
|Related CAS||1132827-21-4 (2HCl)|
|Synonyms||1-(5-(tert-butyl)isoxazol-3-yl)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea; AC220; AC 220; AC-220; AC010220; AC-010220; AC 010220; AC010220; Quizartinib|
|Solubility||Soluble in DMSO|
|Application||treatment of Acute myeloid leukaemia(AML).|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Cancer Research UK; Cardiff University; Daiichi Sankyo Company; University of Texas M. D. Anderson Cancer Center|
Tandutinib, also known as MLN 518, is a piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autopho...
UNC-2025 hydrochloride is the hydrochloride salt of UNC-2025, which is the Mer/FLT3 dual inhibitor.
SU11652 is a cell-permeable and sunitinib-like inhibitor of tyrosine kinase receptor (RTK) and angiogenesis with antineoplastic property. It selectively inhibit...
AC 220 dihydrochloride
AC 220 dihydrochloride is a potent and selective inhibitor of FMS-like tyrosine kinase-3 (FLT3) used for the treatment of AML.
UNC-2025 is a novel potent and highly orally bioavailable Mer/FLT3 dual inhibitor, capable of inhibiting Mer phosphorylation in vivo, following oral dosing as d...
Gilteritinib, also known as (ASP2215, is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT...
SU4984 is a FLT3 inhibitor that induces growth arrest, apoptosis, and cell cycle arrest in Ba/F3 and AML cell lines expressing a constitutively activated FLT3. ...
This active molecular also known as AC220 and AC010220, is developed as a new second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM, ten ...
CHMFL-FLT3-122 is a potent and selective FLT3 inhibitor (IC50 = 40 nM) with >10-fold and 170-fold selectivity for FLT3 over BTK kinase and c-KIT kinase. It caus...
BPR1J-097 is a novel potent FLT3 inhibitor with an IC50 of 11 nM.
TCS-359 is a potent inhibitor of FLT3 with IC50 of 42 nM.
FLT3-IN-1, a Flt3 inhibitor, has been found to have week activity against T lymphoma Jurkat cells and human lung cancer PC-9 and H292 cells. IC50: 10 nM (in vit...
SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cel...
KW-2449 is a novel multikinase inhibitor, which suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Recent resea...
5'-Fluoroindirubinoxime is an inhibitor of FMS-like receptor tyrosine kinase-3 (FLT3) (IC50 = 15 nM) with antiproliferative activity. It displays selectivity fo...
AST487 is a Ret kinase inhibitor/FLT3 inhibitor, which displays high selectivity and potency toward FLT3 as a molecular target, and which could potentially be u...
G-749 potently inhibits autophosphorylation of FLT3 with IC50 of ≤8 nM. In leukemia cells, G-749 shows antiproliferative activity by inducing apoptosis.